Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Novartis has formed a partnership with IFM Due, a subsidiary of IFM Therapeutics that is focused on developing inhibitors of the cGAS/stimulator of interferon genes (STING) pathway. Novartis is already developing activators of the STING protein for cancer, and is one of several companies that believes STING inhibitors would make powerful therapies for autoimmune and inflammatory diseases. Novartis will assume all of IFM Due’s R&D costs and may acquire the company for up to $840 million in the future.
This article has been sent to the following recipient: